GlaxoSmithKline (GB:GSK) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
GlaxoSmithKline (GSK) has announced encouraging results from a phase II trial of its mRNA seasonal influenza vaccine, which showed positive immune responses in both younger and older adults compared to current vaccines. The trial’s success paves the way for phase III clinical trials, marking significant progress in GSK’s mRNA vaccine development. The company aims to offer a new best-in-class vaccine, bolstering its capabilities through strategic partnerships and investments in AI and manufacturing technologies.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
